• Media type: E-Article
  • Title: Validation of 111In-Exendin SPECT for the Determination of the β-Cell Mass in BioBreeding Diabetes-Prone Rats
  • Contributor: Brom, Maarten; Joosten, Lieke; Frielink, Cathelijne; Peeters, Hanneke; Bos, Desirée; van Zanten, Monica; Boerman, Otto; Gotthardt, Martin
  • imprint: American Diabetes Association, 2018
  • Published in: Diabetes
  • Language: English
  • DOI: 10.2337/db17-1312
  • ISSN: 0012-1797; 1939-327X
  • Keywords: Endocrinology, Diabetes and Metabolism ; Internal Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>The changes in β-cell mass (BCM) during the development and progression of diabetes could potentially be measured by radionuclide imaging using radiolabeled exendin. In this study, we investigated the potential of 111In-diethylenetriaminepentaacetic acid–exendin-3 (111In-exendin) in a rat model that closely mimics the development of type 1 diabetes (T1D) in humans: BioBreeding diabetes-prone (BBDP) rats. BBDP rats of 4–18 weeks of age were injected intravenously with 111In-exendin, and single-photon emission computed tomography (SPECT) images were acquired. The accumulation of the radiotracer was measured as well as the BCM and grade of insulitis by histology. 111In-exendin accumulated specifically in the islets, resulting in a linear correlation with the BCM (%) (Pearson r = 0.89, P &amp;lt; 0.0001, and r = 0.64 for SPECT). Insulitis did not have an influence on this correlation. These results indicate that 111In-exendin is a promising tracer to determine the BCM during the development of T1D, irrespective of the degree of insulitis.</jats:p>
  • Access State: Open Access